The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941 · cited 1×
“For evaluation of liver dysfunction, Child-Pugh score was calculated based on the composite score of five variables: bilirubin, albumin, ascites, encephalopathy, and international normalized ratio [12].”
MethodCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Johnson, P. J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H. L., O'Beirne, J., Fox, R., Skowronska, A., Palmer, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9151 · Cited by 2,783
Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice
Singal, A. G., & El-Serag, H. B. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.08.014 · Cited by 530
Miller, A. A., Murry, D. J., Owzar, K., Hollis, D. R., Kennedy, E. B., Abou-Alfa, G., Desai, A., Hwang, J., Villalona-Calero, M. A., Dees, E. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0931 · Cited by 206
Current and future treatments for hepatocellular carcinoma
Schlachterman, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i28.8478 · Cited by 171
Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma
Samuel, M., Chow, P. K. H., Shih‐Yen, E. C., Machin, D., & Soo, K. C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001199.pub2 · Cited by 158
Pressiani, T., Boni, C., Rimassa, L., Labianca, R., FAGIUOLI, S., Salvagni, S., Ferrari, D., Cortesi, E., Porta, C., Mucciarini, C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds343 · Cited by 154
Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective
Brose, M. S., Frenette, C. T., O’Keefe, S. J., & Stein, S. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.01.001 · Cited by 141
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
Hollebecque, A., Cattan, S., Romano, O., Sergent, G., Mourad, A., Louvet, A., Dharancy, S., Boleslawski, E., Truant, S., Pruvot, F., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04860.x · Cited by 119
Abou‐Alfa, G. K., Amadori, D., Santoro, A., Figer, A., Grève, J. D., Lathia, C. D., Voliotis, D., Anderson, S. E., Moscovici, M., & Ricci, S. (2011) · Europe PMC (PubMed Central) · Cited by 109
Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
Otsuka, T., Eguchi, Y., Kawazoe, S., Yanagita, K., Ario, K., Kitahara, K., Kawasoe, H., Kato, H., Mizuta, T., & the Saga Liver Cancer Study Group (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.00991.x · Cited by 100
Sorafenib: from literature to clinical practice
Marco, V. D., Vita, F. D., Koskinas, J. S., Semela, D., Toniutto, P., & Verslype, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt055 · Cited by 85
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
Kim, J. E., Ryoo, B., Ryu, M., Chang, H.-M., Suh, D. J., Lee, H. C., Lim, Y., Kim, K. M., & Kang, Y. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1616-x · Cited by 85
Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib
Ozenne, V., Paradis, V., Pernot, S., Castelnau, C., Vullierme, M., Bouattour, M., Valla, D. C., Farges, O., & Degos, F. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283386053 · Cited by 72
Lencioni, R. A., Marrero, J., Venook, A. P., Ye, S.-L., & Kudo, M. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02414.x · Cited by 67
Self-citationSkin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma
Shomura, M. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i9.670 · Cited by 34
Monsour, H., Asham, E. H., McFadden, R., Victor, D. W., Muthuswamy, B., & Zaheer, I. (2013) · Translational Cancer Research · doi:10.21037/1864 · Cited by 14
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“[335] There are emerging data for safety of other mTKI agents, such as lenvatinib, in patients with Child-Turcotte-Pugh B liver disease as well.”
Self-citationMolecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Metadata
- Authors
- Marrero, J. A., Kudo, M., Venook, A. P., Ye, S.-L., Bronowicki, J.-P., Chen, X.-P., Dagher, L., Furuse, J., Geschwind, J.-F. H., de Guevara, L. L., Papandreou, C., Takayama, T., Sanyal, A. J., Yoon, S. K., Nakajima, K., Lehr, R., Heldner, S., & Lencioni, R.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 65
- Issue
- 6
- Pages
- 1140-1147
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2502891277
- Cited by
- 385
- References
- 23
- FWCI
- 19.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.